- Correction
- Open access
- Published:
Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
Journal of Experimental & Clinical Cancer Research volume 41, Article number: 40 (2022)
Correction to: J Exp Clin Cancer Res 40, 364 (2021).
https://doi.org/10.1186/s13046-021-02154-8
Following publication of the original article [1], the authors identified errors Figs. 3, 4, 5 and 6 specifically:
Figure 3d - Percentage of HCC cells in G0/G1, S and G2/M phase of the cell cycle by PI staining and flow cytometry analysis. Data are expressed as mean ± SD of at least three independent experiments and analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT
Figure 4b - Quantitative analysis and representative pictures of in vivo bioluminescence imaging analysed before administration of compounds (day 0) and during treatments at days 14, 21, 28 or 35. Luminescent signals are expressed as mean ± SD of total flux of photons/sec/cm2/steradian (p/s/cm2/sr). Data were analysed by ANOVA test. (**p < 0.01 n = 6). Representative images of immunofluorescence for PCNA (in red)
Figure 5a, b, c - Heatmap representation of the expression of up-regulated; cancer-related genes in HepG2 and Huh7 cells in TAE226 > SOR compared to NT cells; Venn diagrams showing the overlapping of up-regulated (upper circles) and down-regulated (lower circles) genes in HepG2 and Huh7 cells treated with TAE226 > SOR compared to NT cells.
Figure 6c - EZH2 expression after treatments, in HepG2 and Huh7 cells. αTubulin served as loading control. Values are the mean of arbitrary units ± SD of at least three independent experiments. Data were analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT
In addition, the revised Supplementary materials also need to be corrected specifically, Additional files 6, 7 and 8.
The authors provided the Journal with the original data files. The corrected figures are given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.
Reference
Romito I, Porru M, Braghini MR, et al. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res. 2021;40:364. https://doi.org/10.1186/s13046-021-02154-8.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Romito, I., Porru, M., Braghini, M.R. et al. Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res 41, 40 (2022). https://doi.org/10.1186/s13046-022-02247-y
Published:
DOI: https://doi.org/10.1186/s13046-022-02247-y